Drug from Fresenius Kabi now available in the U.S. after Emergency Use Authorization

Following the recent U.S. Food and Drug Administration (FDA) Emergency Use Authorization, Fresenius Kabi Propoven 2% is now available in the U.S. Propoven 2% is a higher concentrated dosage form of propofol compared to Fresenius Kabi’s FDA-approved Diprivan® 1%, providing clinicians with another sedation option for ventilated COVID-19 patients. The higher concentration presentation allows Fresenius Kabi to support more patients through more efficient use of existing manufacturing capacity.